Randomised trial of hyperimmune immunoglobulin in hospitalised COVID-19: pre-therapy Fc receptor binding SARS-CoV-2 antibody associated with better outcomes.

BACKGROUND: Neutralising monoclonal antibodies prevent and treat COVID-19 if administered early after infection with sensitive SARS-CoV-2 variants. Despite containing high neutralising antibodies, hyperimmune intravenous immunoglobulin (hIVIG) generally fails to mitigate severe COVID-19. We probed potential reasons for this discrepancy in a recent large, randomised trial (NCT04546581). METHODS: Multiplex bead arrays were used to measure SARS-CoV-2 specific FcγR binding and neutralising activity in pre-treatment sera from 481 subjects (231 placebo vs. 250 hIVIG). Associations between pre-therapy antibody FcγR engagement and day 7 clinical outcome were evaluated. RESULTS: Elevated levels of FcγRIIIa engagement by baseline spike (S)-specific antibody were associated with better clinical outcomes in COVID-19 hospitalised patients across both hIVIG- and placebo-treated groups (OR=0.43, 95%CI 0.30-0.63). Higher nucleocapsid (N) antibody-mediated FcγR engagement and surrogate neutralisation in pre-treatment sera were also modestly associated with improved outcomes. Higher pre-therapy S-specific FcγR binding antibody was also associated with reduced SARS-CoV-2 viral loads. CONCLUSIONS: Higher pre-therapy S-specific FcγR binding antibody, but not additional FcγR binding antibody provided by hIVIG, was associated with improved outcomes in severe COVID-19. Pre-existing FcγR engaging antibody, along with rapid production of these antibodies in placebo-treated subjects, may dilute potential benefits from hIVIG therapy. This work helps guide development of more strategic, targeted treatment of severe SARS-CoV-2 infection with antibody-based therapeutics.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-14
DOI
https://doi.org/10.1093/infdis/jiag561
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Randomised trial of hyperimmune immunoglobulin in hospitalised COVID-19: pre-therapy Fc receptor binding SARS-CoV-2 antibody associated with better outcomes.

Sarah Lilian Pett, Kevin John Selva, Jens‐Ulrik Stæhr Jensen, Stephen John Kent et al.
PubMed
SARS-CoV-2 and COVID-19 Research
article

Randomised trial of hyperimmune immunoglobulin in hospitalised COVID-19: pre-therapy Fc receptor binding SARS-CoV-2 antibody associated with better outcomes.

Sarah Lilian Pett, Kevin John Selva, Jens‐Ulrik Stæhr Jensen, Stephen John Kent, Hillary A. Vanderven, Mark Niccolo Polizzotto, Cavan Reilly, Anthony Dominic Kelleher, Amy W. Chung, Win Min Han, Sean Liu, Zaiyah Habib
article en

Abstract

BACKGROUND: Neutralising monoclonal antibodies prevent and treat COVID-19 if administered early after infection with sensitive SARS-CoV-2 variants. Despite containing high neutralising antibodies, hyperimmune intravenous immunoglobulin (hIVIG) generally fails to mitigate severe COVID-19. We probed potential reasons for this discrepancy in a recent large, randomised trial (NCT04546581). METHODS: Multiplex bead arrays were used to measure SARS-CoV-2 specific FcγR binding and neutralising activity in pre-treatment sera from 481 subjects (231 placebo vs. 250 hIVIG). Associations between pre-therapy antibody FcγR engagement and day 7 clinical outcome were evaluated. RESULTS: Elevated levels of FcγRIIIa engagement by baseline spike (S)-specific antibody were associated with better clinical outcomes in COVID-19 hospitalised patients across both hIVIG- and placebo-treated groups (OR=0.43, 95%CI 0.30-0.63). Higher nucleocapsid (N) antibody-mediated FcγR engagement and surrogate neutralisation in pre-treatment sera were also modestly associated with improved outcomes. Higher pre-therapy S-specific FcγR binding antibody was also associated with reduced SARS-CoV-2 viral loads. CONCLUSIONS: Higher pre-therapy S-specific FcγR binding antibody, but not additional FcγR binding antibody provided by hIVIG, was associated with improved outcomes in severe COVID-19. Pre-existing FcγR engaging antibody, along with rapid production of these antibodies in placebo-treated subjects, may dilute potential benefits from hIVIG therapy. This work helps guide development of more strategic, targeted treatment of severe SARS-CoV-2 infection with antibody-based therapeutics.

PubMed
Australian National University (AU), University of Copenhagen (DK), University of Minnesota (US), The University of Melbourne (AU), Australian Institute of Tropical Health and Medicine (AU), Copenhagen University Hospital (DK), Gentofte Hospital (DK), UNSW Sydney (AU), MRC Clinical Trials Unit at UCL (GB), Peter Doherty Institute (AU), Institute of Human Virology (NG), Kirby Institute (AU), University College London (GB), James Cook University (AU), Medical Research Council (GB), Icahn School of Medicine at Mount Sinai (US)
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon